Mo Kyumin, Kim Ayoung, Choe Soohyun, Shin Miyoung, Yoon Hyunho
Department of Medical and Biological Sciences, The Catholic University of Korea, Bucheon 14662, Republic of Korea.
Department of Biotechnology, The Catholic University of Korea, Bucheon 14662, Republic of Korea.
Pharmaceutics. 2023 Jul 31;15(8):2065. doi: 10.3390/pharmaceutics15082065.
Lipid nanoparticles (LNPs), composed of ionized lipids, helper lipids, and cholesterol, provide general therapeutic effects by facilitating intracellular transport and avoiding endosomal compartments. LNP-based drug delivery has great potential for the development of novel gene therapies and effective vaccines. Solid lipid nanoparticles (SLNs) are derived from physiologically acceptable lipid components and remain robust at body temperature, thereby providing high structural stability and biocompatibility. By enhancing drug delivery through blood vessels, SLNs have been used to improve the efficacy of cancer treatments. Breast cancer, the most common malignancy in women, has a declining mortality rate but remains incurable. Recently, as an anticancer drug delivery system, SLNs have been widely used in breast cancer, improving the therapeutic efficacy of drugs. In this review, we discuss the latest advances of SLNs for breast cancer treatment and their potential in clinical use.
脂质纳米颗粒（LNPs）由离子化脂质、辅助脂质和胆固醇组成，通过促进细胞内运输和避开内体区室发挥一般治疗作用。基于LNP的药物递送在新型基因治疗和有效疫苗的开发方面具有巨大潜力。固体脂质纳米颗粒（SLNs）由生理上可接受的脂质成分制成，在体温下保持稳定，从而具有高结构稳定性和生物相容性。通过增强药物经血管递送，SLNs已被用于提高癌症治疗的疗效。乳腺癌是女性中最常见的恶性肿瘤，其死亡率虽在下降，但仍无法治愈。近年来，作为一种抗癌药物递送系统，SLNs已被广泛应用于乳腺癌治疗，提高了药物的治疗效果。在这篇综述中，我们讨论了SLNs在乳腺癌治疗方面的最新进展及其临床应用潜力。
